Lilly | Chorus Link to Link to Chorus Home Page
This text will be replaced
Chorus, an autonomous division of Eli Lilly and Company, is an early phase drug development group that cost-effectively advances candidate molecules from discovery through clinical Proof of Concept (PoC).

The Chorus mission is to deliver definitive, quality PoC data enabling our business partners to efficiently sort a large stream of innovative candidates. The goal of Chorus is to deliver PoC data that permits informed go-no go investment decisions and, in the case of successful assets, drives a large step-up in probability of technical success and value. We do this by combining an integrated, virtual drug development platform with a more efficient drug development paradigm to deliver best-in-industry productivity. Taking the Chorus approach to early stage development, our business partners can markedly reduce the cost of early technical attrition while maintaining a call back option for promising assets. More>>
What has:
1) the agility of a start up company to efficiently and effectively advance a new molecule to clinical Proof of Concept;

2) the leverage, resources and reputation of one of the world's leading Pharmaceutical companies; and

3) the track record of achieving innovative global drug development?

The Answer?